Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Public Health
Published in: International Journal of Public Health 6/2016

01-07-2016 | Original Article

Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel

Authors: Gary M. Ginsberg, Colin Block, Chen Stein-Zamir

Published in: International Journal of Public Health | Issue 6/2016

Login to get access

Abstract

Objectives

Using cost-utility analysis, to evaluate whether or not to adopt a Neisseria meningitidis serogroup B vaccination programme for Israeli children.

Methods

Epidemiological, demographic, health service utilisation and economic data were integrated into a spreadsheet model to calculate the cost per averted disability-adjusted life year (DALY) of the intervention.

Results

Assuming 78 % vaccine efficacy with no herd immunity, vaccination will prevent 223 cases and 22 deaths over a 100-year period. Based on vaccine price of $60 per dose, total intervention costs ($315,400,000) are partially offset by a $22,700,000 reduction in treatment and sequelae costs as a result of decreased morbidity. The intervention was not cost-effective since the net cost ($292,700,000) per averted DALY gained (1249 mostly due to decreased mortality) was $234,394. Additional two dose catch-up programmes vaccinating children in cohorts aged 1–2 to 1–13 were also not cost-effective.

Conclusions

The vaccination will become cost-effective if vaccine costs fall below $19.44 per dose. However, in identified high risk areas, the vaccine would be cost-effective and could be recommended for use both with and without catch-up campaigns.
Appendix
Available only for authorised users
Literature
Arnold R, Galloway Y, McNicholas A, O’Hallahan J (2011) Effectiveness of a vaccination program for an epidemic of meningococcal B in New Zealand. Vaccine 29:7100–7106CrossRefPubMed
Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R, For the members of the Canadian immunization Monitoring Program Active (IMPACT) (2013) The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J 32:e20–e25. doi:10.​1097/​INF.​0b013e3182706b89​ CrossRefPubMed
Buysse CMP, Raat H, Hazelet JA et al (2008) Long-term health status in childhood survivors of meningococcal septic shock. Arch Pediatr Adolesc Med 162:1036–1041CrossRefPubMed
Buysse CM, Oranje AP, Zuidema E, Hazalet JA, Hop WCJ, Diepstaten AF, Joosten KFM (2009) Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock. Arch Dis Child 94:381–386CrossRefPubMed
Buysse CMP, Vermunt LCAC, Raat H, Hazalet JA, Hop WCJ, Utens EMWJ, Joosten KFM (2010) Surviving meningococcal septic shock in childhood: long-term overall outcome and the effect of health-related quality of life. Crit Care 14:R124. doi:10.​1186/​cc9087 (Published Online 29 June 2010)
Central Bureau of Statistics (2015) Annual Statistical Abstract 2015. CBS, Jerusalem
Centres for Disease Control and Prevention (2005) Prevention and control of meningococcal disease recommendations of the advisory committee on immunization practices (ACIP). MMWR 54:1–21
Chandran A, Herbert H, Misurski D, Santashan M (2011) Long-term sequelae of childhood bacterial meningitis. Pediatr Infect Dis J 30:3–6CrossRefPubMed
Christensen H, May M, Bowen L, Hickman M, Trotter CL (2010) Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 10:853–861CrossRefPubMed
Christensen H, Hickman M, Edmunds WJ, Trotter CL (2013) Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 31:2638–2646CrossRefPubMedPubMedCentral
Christensen H, Trotter CL, Hickman M, Edmunds WJ (2014) Re-evaluating cost effectiveness of universal meningitis vaccination (Bexero) in England: modelling study. BMJ 349:g5725CrossRefPubMedPubMedCentral
Delbos V, Lemée L, Bénichou J et al (2013) Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage. Vaccine 31:4416–4420CrossRefPubMed
Dellicour S, Greenwood B (2007) Systematic review: impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop Med Int Health 12:1409–1421CrossRefPubMed
Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I (2010) Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 10:317–332CrossRefPubMed
Edwards MS, Baker CJ (1981) Complications and sequelae of meningococcal infections in children. J Pediat 99(4):540–545CrossRefPubMed
Erickson L, De Wals P (1998) Complications and sequelae of meningococcal disease in Quebec, Canada, 1990–1994. Clin Infect Dis 26:1159–1164CrossRefPubMed
Frosi G, Biolchi A, Sapio ML et al (2013) Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 31:4968–4974CrossRefPubMed
Ginsberg GM, Kark J, Einav S (2015) Cost utility analysis of cardiac resuscitation services in Jerusalem. Resuscitation 86:54–61CrossRefPubMed
Gorringe AR, Pajon R (2012) Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum Vaccines Immunother 8:174–183CrossRef
Gossger N, Snape MD, Yu LM, European MenB Vaccine Study Group et al (2012) Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 307(6):573–582CrossRefPubMed
Healy CM, Butler KM, Smith EO et al (2002) Influence of serogroup on the presentation, course, and outcome of invasive meningococcal disease in children in the Republic of Ireland, 1995–2000. Clin Infect Dis 34:1323–1330CrossRefPubMed
Holst J, Feiring B, Fuglesang JE, Høiby EA, Nøkleby H, Aaberge IS, Rosenqvist E (2003) Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitis serogroup B disease. Vaccine 21:734–737CrossRefPubMed
Huels J, Wassil J, Bonefeld L, Watson P (2013) Sensitivity analysis of a model used to predict the cost effectiveness of bexero for immunisation against meningococcal disease in the United Kingdom. In: Poster presented at meningitis and septacemia in children and adults, 5–6 November 2013, London
Israel Center for Disease Control (2012) Notifiable infectious diseases in Israel, 60 years of surveillance 1951–2010. Publication No. 342
Izuierdo G, Torres JP, Santolya ME, Valenzuela MT, Vega J, Chomali M (2015) Cost-effectiveness analysis of a multicomponent meningococcal serogroup B (4CMeb B) vaccine in epidemic situation in a middle-income country. Hum Vaccine Immunother 11:875–883. doi:10.​1080/​21645515.​2015.​1010885 CrossRef
Jacobs P, Noseworthy TW (1990) National estimates of intensive care utilization and costs. Crit Care Med 18:1282–1286CrossRefPubMed
Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 Causes of Death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–2128CrossRefPubMed
McNicholas A, Galloway Y, Stehr-Green P et al (2007) Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004–2006. Hum Vaccines 3:196–204CrossRef
Meningococcal B Pilot Project Task Group (2014). The recommended use of the multicomponent meningococcal B (4CMENB) vaccine in Canada: common guidance statement. Ottawa
Pouwels KB, Hak E, van der Ende A, Christenden H, van der Dobbelstein GP, Postma MJ (2013) Cost-effectiveness of vaccination against meningococcal B among Dutch infants. Hum Vaccines Immunother 9:1–10CrossRef
Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E (2003) Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326:365–366CrossRefPubMedPubMedCentral
Read RC, Baxter D, Chadwick DRI et al (2014) Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 384:2123–2131CrossRefPubMed
Scholten RJ, Bijlmer HA, Valkenburg HA, Dankert J (1994) Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis. Epidemiol Infect 112:115–124CrossRefPubMedPubMedCentral
Scott RD, Meltzer MI, Erikson LJ, DeWals P, Rosenstein NE (2002) Vaccinating first-year college students living in dormitories for meningococcal disease. Am J Prev Med 23:98–105CrossRefPubMed
Slack R, Hawkins KC, Gilhooley L, Addison GM, Lewis MA, Webb NJA (2005) Long-term outcome of meningococcal sepsis-associated acute renal failure. Pediatr Crit Care Med 6:477–479CrossRefPubMed
Stein-Zamir C, Abramson N, Zentner G, Sloob H, Valinsky L, Block C (2008) Invasive meningococcal disease in children in Jerusalem. Epidemiol Infect 136:82–89
Stein-Zamir C, Shoob H, Sokolov I, Kunbar A, Abramson N, Zimmerman D (2014) The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis J 33:777–779CrossRefPubMed
Trotter CL, Edmunds WJ (2006) Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med Decis Mak 26:38–47CrossRef
Trotter CL, Andrews NJ, Zaczmarski EB, Miller E, Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365–367CrossRefPubMed
Tu HA, Deeks SL, Morris SK et al (2014) Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. Vaccine 32:5436–5446CrossRefPubMed
Vesikari T, Eposito S, Ypma E et al (2013) Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMEN B) administered concomitantly with routine infant and child vaccinations: results of two randomized trials. Lancet 381:825–35 (Erratum in: Lancet (2013) 381: 804)
Viner RE, Booy R, Johnson H et al (2012) Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol 11:774–783CrossRefPubMed
WHO Commission on MacroEconomics and Health (2001) Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. World Health Organization, Geneva, p 2001
World Health Organization (1996) Murray CJL, Lopez AD (eds) The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. WHO, USA
Wright C, Wordsworth R, Glennie L (2013) Counting the cost of meningococcal disease: scenarios of severe meningitis and septicemia. Paediatr Drugs 15:49–58CrossRefPubMed
Metadata
Title
Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel
Authors
Gary M. Ginsberg
Colin Block
Chen Stein-Zamir
Publication date
01-07-2016
Publisher
Springer International Publishing
Published in
International Journal of Public Health / Issue 6/2016
Print ISSN: 1661-8556
Electronic ISSN: 1661-8564
DOI
https://doi.org/10.1007/s00038-016-0821-0

Other articles of this Issue 6/2016

International Journal of Public Health 6/2016 Go to the issue

Original Article

Main competences and skills to perform Essential Public Health Operations, offered by Schools of Public Health in four European countries: a short pilot report

Original Article

Utilization of health-care services among immigrants recruited through non-profit organizations in southern Italy

Original Article

Predictors of nicotine withdrawal symptoms: findings from the first randomized smoking cessation trial in a low-income country setting

Editorial

Fifty years of serving public health: the Association of Schools of Public Health in the European Region moving forward to the next half-century

Original Article

Stunting and weight statuses of adolescents differ between public and private schools in urban Gambia

Original Article

Effectiveness of health warnings for waterpipe tobacco smoking among college students